Immunic Appoints New CMO, Dr. Marneros Departs
Ticker: IMUX · Form: 8-K · Filed: Apr 28, 2026 · CIK: 0001280776
| Field | Detail |
|---|---|
| Company | Immunic, Inc. (IMUX) |
| Form Type | 8-K |
| Filed Date | Apr 28, 2026 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel
TL;DR
New CMO at Immunic, old one out. Patel in, Marneros out.
AI Summary
On April 24, 2026, IMMUNIC, INC. filed an 8-K report detailing the departure of Dr. Andreas M. Marneros from his role as Chief Medical Officer. The company also announced the appointment of Dr. Saurabh K. Patel as the new Chief Medical Officer, effective immediately. Additionally, the filing includes information regarding compensatory arrangements for certain officers.
Why It Matters
This filing signifies a leadership change in a critical medical role, which could impact the company's drug development pipeline and strategic direction.
Risk Assessment
Risk Level: medium — Leadership changes, especially in key executive roles like Chief Medical Officer, can introduce uncertainty and potential shifts in strategy.
Key Players & Entities
- IMMUNIC, INC. (company) — Filer of the 8-K report
- Dr. Andreas M. Marneros (person) — Departing Chief Medical Officer
- Dr. Saurabh K. Patel (person) — Appointed Chief Medical Officer
- April 24, 2026 (date) — Effective date of the reported changes
FAQ
What was the effective date of Dr. Marneros' departure?
The filing indicates the reporting period ended on April 24, 2026, and the changes related to officer positions are effective as of this period.
Who has been appointed as the new Chief Medical Officer?
Dr. Saurabh K. Patel has been appointed as the new Chief Medical Officer.
What other items are covered in this 8-K filing?
The filing also covers Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits).
What is the CIK number for IMMUNIC, INC.?
The CIK number for IMMUNIC, INC. is 0001280776.
What is the business address of IMMUNIC, INC.?
The business address of IMMUNIC, INC. is 1200 AVENUE OF THE AMERICAS SUITE 200 NEW YORK X1 10036.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 28, 2026 by Dr. Andreas M. Marneros regarding IMMUNIC, INC. (IMUX).